1. Home
  2. HOTH vs NCNA Comparison

HOTH vs NCNA Comparison

Compare HOTH & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hoth Therapeutics Inc.

HOTH

Hoth Therapeutics Inc.

HOLD

Current Price

$0.95

Market Cap

16.6M

Sector

Health Care

ML Signal

HOLD

Logo NuCana plc

NCNA

NuCana plc

HOLD

Current Price

$2.94

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOTH
NCNA
Founded
2017
1997
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.6M
13.8M
IPO Year
2019
2017

Fundamental Metrics

Financial Performance
Metric
HOTH
NCNA
Price
$0.95
$2.94
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$4.50
N/A
AVG Volume (30 Days)
649.7K
87.6K
Earning Date
11-12-2025
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$2.78
52 Week High
$2.12
$268.00

Technical Indicators

Market Signals
Indicator
HOTH
NCNA
Relative Strength Index (RSI) 34.97 34.14
Support Level $1.00 $2.89
Resistance Level $1.13 $3.35
Average True Range (ATR) 0.07 0.19
MACD -0.00 -0.03
Stochastic Oscillator 11.96 9.24

Price Performance

Historical Comparison
HOTH
NCNA

About HOTH Hoth Therapeutics Inc.

Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).

About NCNA NuCana plc

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.

Share on Social Networks: